Condition: Chemotherapy-induced Peripheral Neuropathy (CIPN) · Sponsor: Qilu Pharmaceutical Co., Ltd.
This study is a randomized, double-blind, multicenter, placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of GM1 in preventing chemotherapy-induced peripheral neuropathy in breast cancer patients treated with Albumin-paclitaxel chemotherapy regimen.
This description comes directly from the study's public registry record.
ZeFei Jiang, Chief Physician · 010-66947175 · jzf_cscobc@csco.org.cn
Always discuss trial participation with your own doctor first.
| The Fifth Medical Center of the Chinese People's Liberation Army General Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06994507